Iterum Therapeutics PLC
ITRM0.302USD
+0.017+5.89%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
14.80MMarket Cap
LossP/E TTM
More Details of Iterum Therapeutics PLC Company
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Iterum Therapeutics PLC Info
Ticker SymbolITRM
Company nameIterum Therapeutics PLC
IPO dateMay 25, 2018
CEOFishman (Corey N)
Number of employees9
Security typeOrdinary Share
Fiscal year-endMay 25
Address3 Dublin Landings
CityDUBLIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIreland
Postal codeD01 C4E0
Phone35319038354
Websitehttps://www.iterumtx.com/
Ticker SymbolITRM
IPO dateMay 25, 2018
CEOFishman (Corey N)
Company Executives of Iterum Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Michael W. Dunne, M.D.
Dr. Michael W. Dunne, M.D.
Director
Director
241.00K
+6000.00%
Mr. Corey N. Fishman
Mr. Corey N. Fishman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.06K
--
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Independent Director
Independent Director
18.84K
--
Ms. Judith M. Matthews
Ms. Judith M. Matthews
Chief Financial Officer
Chief Financial Officer
8.13K
--
Mr. David G. Kelly
Mr. David G. Kelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Joseph John (Joe) Whalen
Mr. Joseph John (Joe) Whalen
Independent Director
Independent Director
--
--
Ms. Christine Coyne
Ms. Christine Coyne
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Michael W. Dunne, M.D.
Dr. Michael W. Dunne, M.D.
Director
Director
241.00K
+6000.00%
Mr. Corey N. Fishman
Mr. Corey N. Fishman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
137.06K
--
Ms. Beth P. Hecht, J.D.
Ms. Beth P. Hecht, J.D.
Independent Director
Independent Director
18.84K
--
Ms. Judith M. Matthews
Ms. Judith M. Matthews
Chief Financial Officer
Chief Financial Officer
8.13K
--
Mr. David G. Kelly
Mr. David G. Kelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Joseph John (Joe) Whalen
Mr. Joseph John (Joe) Whalen
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Feb 5
Updated: Thu, Feb 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Apollon Financial LLC
1.18%
Squarepoint Capital LLP
0.83%
Dunne (Michael W)
0.45%
OneDigital Investment Advisors LLC
0.36%
Fishman (Corey N)
0.26%
Other
96.92%
Shareholders
Shareholders
Proportion
Apollon Financial LLC
1.18%
Squarepoint Capital LLP
0.83%
Dunne (Michael W)
0.45%
OneDigital Investment Advisors LLC
0.36%
Fishman (Corey N)
0.26%
Other
96.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
2.33%
Investment Advisor/Hedge Fund
0.86%
Individual Investor
0.78%
Hedge Fund
0.15%
Research Firm
0.15%
Bank and Trust
0.01%
Other
95.72%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
53
1.86M
3.49%
-2.48M
2025Q3
51
2.44M
5.09%
-582.93K
2025Q2
52
1.58M
3.92%
-2.61M
2025Q1
55
1.53M
3.82%
-2.58M
2024Q4
58
1.64M
5.63%
-1.56M
2024Q3
56
2.45M
10.80%
+569.01K
2024Q2
63
660.22K
3.99%
-1.18M
2024Q1
68
1.18M
7.18%
-978.56K
2023Q4
68
641.88K
4.78%
-516.61K
2023Q3
72
394.43K
3.03%
-679.64K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Apollon Financial LLC
250.25K
0.47%
--
--
Sep 30, 2025
Squarepoint Capital LLP
443.97K
0.83%
-12.89K
-2.82%
Sep 30, 2025
Dunne (Michael W)
241.00K
0.45%
+6.00K
+2.55%
Nov 30, 2025
OneDigital Investment Advisors LLC
191.00K
0.36%
+30.00K
+18.63%
Sep 30, 2025
Fishman (Corey N)
137.06K
0.26%
--
--
Nov 30, 2025
CAPTRUST Financial Advisors
111.60K
0.21%
+100.10K
+870.43%
Sep 30, 2025
Gen-Wealth Partners Inc
82.05K
0.15%
+82.05K
--
Sep 30, 2025
Renaissance Technologies LLC
81.69K
0.15%
-390.21K
-82.69%
Sep 30, 2025
Virtu Americas LLC
47.13K
0.09%
+47.13K
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
Aug 17, 2022
Merger
15→1
